Voyager Therapeutics Logo.jpg
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
March 28, 2019 16:15 ET | Voyager Therapeutics, Inc.
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of...
Voyager Therapeutics Logo.jpg
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains...